ULURU Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported revenues were $5,649,000 compared to $24,799,000 a year ago. Operating Loss was $653,423,000 compared to $815,517,000 a year ago. Loss before Income taxes were $685,982,000 compared to $866,090,000 a year ago. Net loss was $985,982,000 or $0.01 per Basic and diluted per common share compared to $866,090,000 or $0.03 per Basic and diluted per common share a year ago. The net decrease of approximately $19,000 in revenues from the third quarter of 2016 compared to the third quarter of 2015 is primarily attributable to the decrease of approximately $4,000 in Altrazeal® product sales as territories in Europe and the Middle East have not generated product orders consistent with prior year.  Also effecting the decrease in product sales has been the cancellation of the licensing agreement with Altrazeal AG, prior distributor for Latin America, Africa, and parts of Asia, as there have not been any new product orders from these territories.  Another area of decrease has been in licensing fee revenues of $15,000 due to the cancellation of licensing agreements related to Altrazeal® and the recognition of all unamortized licenses fees occurring in the first and second quarters of 2016. For the nine months, the company reported revenues were $378,774,000 compared to $578,444,000 a year ago. Operating Loss was $1,721,432,000 compared to $2,149,522,000 a year ago. Loss before Income taxes were $1,868,567,000 compared to $2,333,742,000 a year ago. Net loss was $1,868,567,000 or $0.03 per Basic and diluted per common share compared to $2,333,742,000 or $0.09 per Basic and diluted per common share a year ago. The net decrease of $199,000 in revenues is primarily attributable to a decrease of approximately $515,000 in Altrazeal® product sales as territories in Europe and the Middle East have not generated product orders consistent with prior year.  Also effecting the decrease in product sales has been the cancellation of the licensing agreement with Altrazeal AG, prior distributor for Latin America, Africa, and parts of Asia, as there have not been any new product orders from these territories. The decrease in Altrazeal® product sales was partially offset by the recognition of unamortized licensing fees of approximately $316,000 related to the cancellation of distribution agreements with three distributors; Altrazeal AG, KunWha Pharmaceutical Co., and Jiangxi Aiqilin Pharmaceuticals Group.